Skip to content

Trial Summary

A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy

Acronym:

UniCAB

ACTRN/NCT /ethics:

NCT03685448

Scientific title:

A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)

Sponsor / Cooperative group:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Trial & Patient Characteristics

Cancer TypeKidney
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream Non-clear Cell Renal Cell Carcinoma
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date11/4/2019
Anticipated End Date30/4/2024

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Francis Parnis
Recruitment StatusRecruiting